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Abstract A fusion gene was constructed consisting of beat 
labile enterotoxiu chain B (LTB) of E. coli genetically linked at 
its C-terminus to the P-subunit of human chorionic gonadotropin 
in translational fusion, under the control of tat promoter and 
LTB signal sequence. Expression of the fusion gene (about 5 1.111 
ml) in E. co& was confirmed by immunobiot analysis using both 
anti-LTB and anti+hCG polyclonal antibodies. The fusion 
protein was efficiently processed and exported to the periplasmic 
space. LTB in the fusion protein retained its ability to hind to 
GM1 ganglioside receptor. Mice immunized with the fusion 
protein produce antibodies that recognize recombinant PhCG and 
the native hCG suggesting its potential use as a contraceptive 
vaccine. 
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1. Introduction 
Human chorionic gonadotropin (hCG), a heterologous 
mammalian placental protein, has been the first choice as a 
target for immunocontra~eption [Il. A member of the family 
of glycoproteins consisting of two dissimilar subunits, cw. and 
p, it is produced by the trophoblast cells during the first tri- 
mester of pregnancy. The a-subunit is similar to that of other 
members of the family but the P-subunit has a distinctive 
amino acid sequence that confers the hormonal specificity. 
To avoid cross-reaction with other members of the glycopro- 
tein family, the P-subunit has been used in contraceptive vac- 
cine preparations. However, being a self protein, PhCG is not 
immunogenic by itself and is, therefore, conjugated to a non- 
self carrier protein. In all the hCG based vaccines that have 
entered clinical trials, conjugation has been achieved through 
chemical conjugation. Gene fusion offers a practical alterna- 
tive to chemical conjugation as it allows the protein to be 
conjugated to a carrier protein through the recombinant 
route. The fusion protein thus obtained would have a consis- 
tent composition unlike that produced by chemical conjuga- 
tion. Cholera toxin chain B (CTB) and heat Iabile entetotoxin 
chain B (LTB) of E. coli have gained interest as fusion part- 
ners in recent years. Oral administration of these proteins 
stimulates both systemic and mucosal immunity 12-61. This 
property can be exploited to produce vaccines that can be 
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delivered orally, not only for infectious disease control but 
also to control mucosal physiological processes such as ferti- 
lity [7]. 
In the present study, LTB was cloned at the N-terminus of 
PhCG to generate a translational fusion gene under the con- 
trol of tat promoter and LTB signal sequence. We report here 
the expression, efficient processing and export of the fusion 
protein to the periplasm in E. coEi. Our studies also indicate 
that the fusion protein could bind to GM1 ganglioside recep- 
tor, the receptor for LTB, in an in vitro receptor binding 
assay and was found to be immunogenic in mice. 
2. Materials and methods 
2.1. Reagents 
Enzymes were purchased from New England Biolabs, USA. Bacto- 
tryptone, Bacto-agar and Bacto-yeast extracts were from Difco Lab- 
o&tories, USA.- Ampicillin, -isopropyl-~-n-thiogala~topyranoside 
(IPTGI. Freund’s comnlete fCFA1 and incomnlete adiuvant (IFAI .., 1 \ \ I  
were obtained from Sigma Chemjcals, USA. Recomb&ant protein 
A was from Boehringer Mannheim, Germany. [32P]a-dCTP was pur- 
chased from Amersham, UK. Goat anti-BhCG and anti-CTB poly- 
clonal antibodies were provided by the reagent bank of the National 
Institute of Immunology, India and anti-goat IgG-HRP conjugate 
was obtained from Vector Laboratories Inc., USA. Purified hCG 
and monoclonal antibodies to hCG were provided by Dr. S.K. Gupta. 
2.2, Bacterial strains and plasmids 
E. coli DH5ol and HBlOl cells were used as bacterial hosts. The 
clone pKGPhCG [8], having PhCG structural gene under the control 
of tat promoter and LTB signal sequence, and plasmid pBSLTB 
(constructed in our laboratory) containing the LTB gene were used 
as the parent clones. It is to be noted that as a result of the cloning 
strateev of LTB in oBSLTB. the termination codon of LTB was 
delete: and a Sac1 &e was introduced at that position. In order to 
generate the fusion construct, the plasmid pBSLTB was digested with 
Sac1 and the LTB structural gene fragment thus released was cloned 
into Sac1 digested pKGPhCG to give an N-terminal translational 
fusion of LTB to @hCG. The resulting construct is designated 
pLTB@hCG. The te~ination codon for the fusion protein was pro- 
vided by PhCG gene present in the pKGPhCG clone. Ligation and 
transformation with various plasmids as well as analysis of the trans- 
formants were carried out using standard techniques [9]. 
2.3. Znducf~on of re&omb~na~t clones and immu~oblot analysis of fusion 
protein 
Cells harboring the r~ombin~t plasmid pLTB@hCG, having the 
LTB insert either in the right or in the reverse orientation, were grown 
in Luria-Be~anj (LB) medium supplemented with ampicillin (50 pg/ 
ml). Freshly su~~tur~ 0.5 Am/ml unit cells were induced with 1 
mM IPTG for 8 h. Unindu~ cells served as controls. Cells were 
harvested by centrifugation and total cell extract was prepared by 
resuspending the cell pellet of 1 ml culture in 50 pl reducing sample 
buffer. Extracts thus prepared were analyzed by 12% SDS-PAGE and 
immunobiot analysis [lo] was carried out using both anti-LTB and 
ant$hCG polyclonal antibodies to check for expression of the fusion 
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protein. To determine the localization of the fusion protein in E. coli, 
total cell extract, periplasmic fraction [l l] and culture supernatant of 
induced and uninduced cells were analyzed by Western immunoblot 
using anti-BhCG antibodies. 
2.4. Receptor binding activity 
The receptor binding capacity of LTB in the fusion protein was 
determined in vitro using a sandwich ELISA. 100 pl of GM1 gang- 
lioside (10 &ml) was coated onto ELISA plates and incubated at 
37°C for 1 h followed by overnight incubation at 4°C. Non-specific 
sites were blocked with 1% lactogen in PBS-Tween followed by suc- 
cessive incubations with 100 pl each of fusion protein, anti-CTB goat 
antiserum (1:lOOO) and anti-goat IgG-HRP conjugate (1:2000), re- 
spectively. All incubations were carried out at 37°C for 1 h each 
followed by thorough washes with 50 mM PBS containing 0.5% 
Tween-20. Subsequent to the final incubation and washes, 0.05% 
ortho-phenylene diamine (OPD) in citrate phosphate buffer (pH 5.0) 
and 1 pi/ml of hydrogen peroxide were added to develop color. The 
reaction was terminated using 50 11 of 5 N HzS04 and the absorbance 
was read at 490 nm. 
2.5. Immunization 
To determine whether the recombinant fusion protein is immuno- 
genic, 100 pl of emulsion of the periplasmic fraction containing the 
fusion protein with CFA was administered to 6-8 week old BALB/c 
inbred mice (n=lO) at fortnightly intervals. Primary immunization 
with CFA was given subcutaneously and the subsequent boosters 
with IFA were given intramuscularly. The mice were bled retro-orbi- 
tally a week after the third booster. Antibody titers were assayed by 
ELISA and were expressed as the last dilution at which the absor- 
bance at 490 nm was above the background level. 
2.6. Colloidal immunogold assay 
The serum samples were pooled and analyzed for the presence of 
sac I 
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Fig. 1. Construction of the fusion plasmid pLTBBhCG. The 309 bp 
LTB fragment lacking the termination codon released by Sac1 diges- 
tion of pBSLTB was cloned into Sac1 linearized pKGBhCG. Fusion 
gene LTBBhCG is thus under the control of LTB signal sequence 
and tat promoter. 
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Fig. 2. Analysis of fusion protein expression. Total cell extract from 
cells grown in the presence or absence of IPTG were prepared by 
suspending 0.5 A&ml unit cells in reducing sample buffer and were 
analyzed by Western blotting. (A) Samples were immunoblotted 
with anti-BhCG polyclonal antibodies. Lanes 6 and 7 represent un- 
induced and induced samples of the clones containing the plasmid 
in the right orientation while lanes 8 and 9 correspond to the unin- 
duced and induced cells of the reverse orientation clones, respec- 
tively. Lanes 1 and 2 are the uninduced and induced cells of the 
parent clone pKGBhCG expressing BhCG, lanes 3 and 4 are the in- 
duced and uninduced control cells which lack the recombinant plas- 
mid. Lane 5 corresponds to the molecular weight markers. The ar- 
rowhead on the right points to the fusion protein and the 
arrowhead on the left points to BhCG. (B) Samples were immuno- 
blotted with anti-LTB polyclonal antibodies. Lane 4 is the positive 
control corresponding to pure LTB. Lanes 5 and 6 correspond to 
uninduced and induced cells harboring the pLTBBhCG plasmid in 
right orientation, respectively. Lanes 7 and 8 correspond to unin- 
duced and induced cells harboring the pLTBBhCG plasmid in re- 
verse orientation. Lanes 9 and 10 are the negative controls consist- 
ing of uninduced and induced cells which lack the recombinant 
plasmid whereas lanes 1 and 2 correspond to uninduced and in- 
duced cells harboring pMMB68 plasmid expressing LTB. Lane 3 is 
the molecular weight marker showing a band at 30 kDa. The ar- 
rowhead on the right points to the fusion protein and the arrow- 
head on the left points to LTB. 
antibodies by colloidal immunogold assay [12]. Colloidal gold solu- 
tion was prepared as described [12] and 1 ml of this solution was 
mixed with 17 pl of 1% KaCOs. To this mixture, 6 pg of purified 
native hCG was added and vortexed for a few seconds. After incuba- 
tion at room temperature (RT) for 5 min, 6 11 of 20% BSA was added 
and the contents were centrifuged at 5000 rpm for 5 min at RT. The 
pellet was resuspended in 50 pl of the supematant containing the 
colloidal gold mixture, discarding the remainder. Nitrocellulose strips 
(BA 85) were dotted with 5 pg of recombinant protein A and dried at 
RT. 40 ~1 of the pooled serum, 10 pl of 50 mM PBS pH 7.2, 10 ~1 of 
hCG-colloidal gold conjugate and finally, 10 ~1 of 10% alkali-treated 
casein were added in the wells of a microtiter plate. The contents were 
thoroughly mixed and nitrocellulose strips (NCS) were placed in the 
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wells. For positive control, the NCS was dotted with PsWso, a mono- 
clonal antibody to hCG. Sera from unimmunized control mice were 
also tested. To determine whether the antibodies could bind to recom- 
binant PhCG, the latter was conjugated to colloidal gold and tested as 
described above. 
3. Results and discussion 
3.1. Analysis of the expression of pLTBPhCG 
The strategy for the construction of the fusion gene plasmid 
pLTBPhCG is shown in Fig. 1. The fusion gene pLTBPhCG 
is thus under the control of tat promoter and LTB signal 
sequence. E. coli cells harboring the recombinant plasmid 
pLTBPhCG with the insert in either the right or the reverse 
orientation were induced with IPTG and an expression level 
of 3-5 kg/ml of fusion protein was observed. Authenticity of 
the fusion protein was confirmed by Western blot analysis 
using both anti-phCG (Fig. 2A) and anti-LTB (Fig. 2B) poly- 
clonal antibodies. A 30 kDa band corresponding to the ex- 
pected size of fusion protein was detected with both antibod- 
ies in induced cells harboring pLTBPhCG only (Fig. 2A, lane 
7; Fig. 2B, lane 6). A band at a slightly higher molecular 
weight was also observed when the samples were blotted 
with anti-LTB antibody (Fig. 2B, lanes 5-8). This is probably 
a non-specific band as it could be observed in the uninduced 
and induced cells harboring the plasmid in reverse orientation. 
However, this band was not picked up when these samples 
were blotted with anti-DhCG antibody (Fig. 2A). The fusion 
protein could not be detected in uninduced cells suggesting a 
stringent control on inducibility. 
In order to check the localization of the expressed product, 
different cellular fractions of induced and uninduced cells har- 
boring the plasmid pLTBPhCG were analyzed. The fusion 
protein band could be detected as a single band in the total 
cell extract and periplasmic fraction of induced cells (Fig. 3, 
lanes 2 and 3) but not in the culture supematant (lane 4). The 
fusion protein could not be detected in the corresponding 
fractions of uninduced cells. The detection of the fusion pro- 
tein in the periplasmic fraction of induced cells indicated that 
the fusion protein was exported across the cytoplasm, into the 
periplasmic space but not secreted further into the extracellu- 
11345sr89 
Fig. 3. Localization of the fusion protein in E. coli. Different cellu- 
lar fractions of cells grown in the presence and absence of 1 mM 
IPTG were electrophoresed on a 12% SDS-PAGE and immuno- 
blotted with anti-OhCG polyclonal antibodies. Lanes 24 represent 
the total cell extract, periplasmic fraction and supernatant of in- 
duced cells harboring pLTBbhCG. Lanes 5-7 represent the corre- 
sponding fractions of uninduced cells. Lanes 8 and 9 correspond to 
induced and uninduced E. coli cells expressing PhCG. MW denotes 
the molecular weight markers. The arrow points to the fusion pro- 
tein and the arrowhead indicates PhCG. 
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Fig. 4. Receptor binding activity of the fusion protein. The ability 
of LTB in the fusion protein to bind to its receptor, GM1 ganglio- 
side, was tested using an in vitro sandwich ELISA. Pure LTB was 
maintained as the positive control. The periplasmic fraction of the 
fusion protein was used for the test. E. coli HBlOl cells and the re- 
actants which were devoid of GM1 ganglioside and the fusion pro- 
tein were used as negative controls. 
lar medium as no protein band could be observed in the 
culture supernatant of induced cells. The reducing environ- 
ment of E. coli cytoplasm is not conducive to the formation 
of disulfide bonds in cysteine rich proteins. It is, therefore, 
important that the protein be secreted to the outer oxidizing 
environment of periplasm or extracellular medium. By virtue 
of exporting the protein to periplasm, partial purification of 
the protein is achieved automatically since the E. coli peri- 
plasm contains only about 4% of the cellular proteins. 
We have previously shown the efficient cleavage of the sig- 
nal peptide and export of PhCG alone to the periplasm in E. 
coli using LTB signal sequence [8]. The detection of only a 
single band in total cell extract and periplasm (Fig. 3) suggests 
that the fusion protein consisting of two mature proteins, 
LTB and PhCG, in translational fusion, could be successfully 
expressed, efficiently processed and exported to the periplasm 
in E. coli using the LTB signal sequence. 
The expression of the fusion protein improved with increas- 
ing concentration of IPTG until 0.5 mM beyond which no 
detectable increase in expression was observed (data not 
shown). The time course of fusion protein expression revealed 
that the level of expression increased with time attaining its 
maximum at 8 h and plateaued at later time points (data not 
shown). 
3.2. Analysis of receptor binding activity 
The periplasmic fraction of E. coli cells harboring 
pLTBPhCG or HBlOl cells were tested for receptor binding 
activity of LTB in the fusion protein using GM1 sandwich 
ELISA. LTB in the fusion protein retained its ability to 
bind to GM1 ganglioside receptor as is evident from the 
high absorbance detected in the periplasmic fraction of E. 
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coli cells containing pLTBBhCG (Fig. 4). However, its binding 
affinity for GM1 was reduced compared to standard LTB 
which was used as the positive control (Fig. 4). The binding 
affinity of the fusion protein to GM1 ganglioside compared to 
LTB, observed in the present study, supports the earlier find- 
ing [13] that fusion of CTB to a relatively large protein could 
alter its affinity for GMI. Background levels of absorbance 
observed in HBlOl cells or control samples that lacked either 
fusion protein or GM1 demonstrate the specificity of the re- 
action. These data clearly suggest that fusion protein is bio- 
logically active in terms of GM1 receptor binding assay. 
3.3. Immunogenicity of the fusion protein 
To establish the immunogenicity of the recombinant fusion 
protein, mice were immunized with fusion protein as described 
in Section 2. Anti-LTB and anti-BhCG antibodies were as- 
sayed by ELISA in serum samples immunized with fusion 
protein. Antibody titers against each component of the fusion 
protein, i.e. LTB and BhCG, were found to be high, however, 
titers against LTB were 1 :lOOOO and against BhCG were 
1:5000. The serum samples from immunized mice were also 
tested for its reactivity to recombinant BhCG and native hCG 
by colloidal immunogold assay. The antisera raised against 
the fusion protein could bind to recombinant BhCG and na- 
tive hCG (data not shown). These data suggest that the fusion 
protein is immunogenic and has a potential to be used as a 
contraceptive vaccine. 
An expression cassette such as described here could be used 
to clone other genes of interest, using LTB as a fusion part- 
ner, thus bypassing the need for chemical conjugation of pro- 
teins, a process which is time consuming and cumbersome. 
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